about
Immunotherapy-associated autoimmune hemolytic anemia.T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyThe paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.Advancing Immune and Cell-Based Therapies Through Imaging.Immunosurveillance by human γδ T lymphocytes: the emerging role of butyrophilins.Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients.Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy.Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.New agents for the management of resistant metastatic breast cancer.New horizons from immunotherapy in malignant pleural mesothelioma.
P2860
Q37655534-7BFF8404-E68E-492A-A626-B46509BD724DQ38376433-60DF5811-A88C-4821-A0B6-AA28B323175CQ38636430-180D4EBA-60A7-4137-8C29-F7A086B63E79Q38749824-38666931-F590-423C-B37F-23158A9BE3FAQ39062949-9A615025-6990-4613-9FF8-F5813D97DA3BQ39167485-156D526E-4AF3-4BF3-ABA5-1F19A3D38957Q39397758-971C5B9C-D9A5-4E49-9156-D7603AD7570AQ40048521-65CB6B0B-8EF2-40AC-A33F-9BEB5C136FADQ41110505-5ECEE5E1-ED8C-4E90-B57E-2ECAEB5AC658Q41934319-0660F32E-FB3A-43E0-844A-5B5DFBEA5DABQ42121129-965DB69C-D18E-4B26-AFF6-0191A0C8FD95Q42323210-98AA6347-B00D-4373-88FA-D490FE1B7133Q42372848-7F64FF3B-67DA-440E-A3A1-50E45D128F11Q45325629-195A3171-440A-4CB9-9BCE-F3612BE09852Q48164881-712D14C1-7F3E-46DB-84F5-FC4972C18B35Q48240854-F56B7D5C-05D8-40A4-8FB5-7290C75D4729Q52672888-2076A373-1895-4069-B252-A28E5AB69A50
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Advances in Cancer Immunotherapy in Solid Tumors
@ast
Advances in Cancer Immunotherapy in Solid Tumors
@en
Advances in Cancer Immunotherapy in Solid Tumors
@nl
type
label
Advances in Cancer Immunotherapy in Solid Tumors
@ast
Advances in Cancer Immunotherapy in Solid Tumors
@en
Advances in Cancer Immunotherapy in Solid Tumors
@nl
prefLabel
Advances in Cancer Immunotherapy in Solid Tumors
@ast
Advances in Cancer Immunotherapy in Solid Tumors
@en
Advances in Cancer Immunotherapy in Solid Tumors
@nl
P2093
P2860
P356
P1433
P1476
Advances in Cancer Immunotherapy in Solid Tumors
@en
P2093
Sarah Shin
Smitha Menon
P2860
P356
10.3390/CANCERS8120106
P407
P577
2016-11-24T00:00:00Z